Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Molecular Pathology Research Laboratory, |
RCV001542169 | SCV001760837 | pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PVS1, PS2, PS4_Supporting, PM2 |
| Ambry Genetics | RCV004039253 | SCV005029394 | likely pathogenic | Inborn genetic diseases | 2023-12-20 | criteria provided, single submitter | clinical testing | The c.1143+2T>A intronic variant results from a T to A substitution two nucleotides after coding exon 4 in the GATA2 gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. The resulting transcript is not expected to trigger nonsense-mediated mRNA decay and the exact functional effect of the altered amino acid sequence is unknown; however, the impacted region is critical for protein function (Ambry internal data). This variant was reported as a de novo occurrence in an individual with myelodysplastic syndrome identified in the bone marrow and RNA studies identified aberrant splicing associated with this variant (Oleaga-Quintas C et al. J Clin Immunol, 2021 Apr;41:639-657). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |